The Conversation (0)
Breathtec BioMedical gave a corporate update to shareholders on recent events and provided an outlook on the company’s future plans.
Breathtec BioMedical (CSE:BTH, OTCQB:BTHCF) gave a corporate update to shareholders on recent events and provided an outlook on the company’s future plans.
As quoted in the press release:
The Company is pleased to announce the formation of a new strategic alliance and research agreement with ZeptoMetrix™ Corporation, an industry leader and innovator for Infectious Disease Diagnostics and Development. Plans include an exploratory study to identify biomarkers associated with the Zika virus. The Company views the development of portable devices designed to screen individuals who may carry infections such as Zika at international points of entry as a significant opportunity for its technology. This is a new and exciting area of interest for the Company as current tests for infectious diseases are expensive and often require time consuming lab testing delays.
“Our extensive experience and expertise in propagation and purification of infectious disease cultures will be a tremendous asset in this relationship,” states Dr. Gregory R. Chiklis, President and CEO of ZeptoMetrix Corporation. “I am excited and pleased in what both ZeptoMetrix™ and Breathtec are committed to bringing to this alliance in order to help provide patients with proper results.”
Click here to read the full press release.
Source: www.marketwired.com